Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Aerie Pharmaceuticals, BioCryst Pharmaceuticals and GW Pharmaceuticals were among the biotech movers in premarket trading on Thursday.

Author:: Armie Margaret Lee
Publish date:: May 25, 2017 9:37 AM EDT

Shares of Aerie Pharmaceuticals (AERI) - Get Report jumped 37.4% to $55.65 in premarket trading on Thursday. The Irvine, Calif.-based firm after the market close on Wedneday unveiled positive topline efficacy results in a phase three study of Roclatan, an eye drop combining Rhopressa (netarsudil ophthalmic solution) with prostaglandin analogue (PGA) latanoprost.

Puma Biotechnology (PBYI) - Get Report shares continue rising after the company's breast cancer treatment neratinib received a recommendation late Wednesday for FDA approval from the agency's Oncologic Drugs Advisory Committee. Thursday the shares were up 1.27% to $75.90 in pre-market trading. The shares are up dramatically since Friday, when they closed at $37.80.

Meanwhile, shares of BioCryst Pharmaceuticals (BCRX) - Get Report rose 19.1% to $6.11. The Research Triangle Park, N.C.-based firm on Thursday announced additional positive results from a second interim analysis of a phase two study of BCX7353 as a preventative treatment to reduce the frequency of attacks in patients with hereditary angioedema.

Other biotech movers include GW Pharmaceuticals (GWPH) - Get Report , whose American depository receipts were up 4.4% to $111. The London firm, together with its U.S. subsidiary Greenwich Biosciences, said Wednesday that The New England Journal of Medicine has published results from a phase three study of Epidiolex (cannabidiol) in children with Dravet syndrome.

Jim Cramer and the AAP team give their analysis of the Federal Reserve's May policy meeting minutes. Find out what they are telling their investment club members. Get a free trial subscription to Action Alerts PLUS.

Meanwhile, over on Real Money, Cramer discusses why the good guys at HP (HPQ) - Get Report won on Wednesday night. Get his insights or analysis with a free trial subscription to Real Money.

Read More Trending Articles: